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. Genome-wide association and large-scale sequencing studies strongly implicate both common variants 2-4 and rare de novo variants [5] [6] [7] [8] [9] [10] in ASD. Recessive mutations have also been implicated [11] [12] [13] [14] but their contribution remains less well defined. Here we demonstrate an excess of biallelic lossof-function and damaging missense mutations in a large ASD cohort, corresponding to approximately 5% of total cases, including 10% of females, consistent with a female protective effect. We document biallelic disruption of known or emerging recessive neurodevelopmental genes (CA2, DDHD1, NSUN2, PAH, RARB, ROGDI, SLC1A1, USH2A) as well as other genes not previously implicated in ASD including FEV (FEV transcription factor, ETS family member), which encodes a key regulator of the serotonergic circuitry. Our data refine estimates of the contribution of recessive mutation to ASD and suggest new paths for illuminating previously unknown biological pathways responsible for this condition.
We performed a systematic analysis of exome data from the Autism Sequencing Consortium (ASC) 15 , representing 2,343 affected and 5,852 unaffected individuals (Supplementary Table 1 and Supplementary Fig. 1 ). We cataloged a total of 696,143 autosomal loss-of-function (LOF) events (representing 28,685 unique variants in 11,745 unique genes) that introduce a stop codon or disrupt a canonical splice site (Table 1) . After excluding common variants (allele frequency > 1%), there were 84,645 rare LOF events (27,648 unique alleles) for an average of approximately 10 LOF mutations per individual. After computational phasing, we found 298 events in the ASC (after filtering to exclude common polymorphisms), which is consistent with complete gene knockout (homozygous or compound heterozygous LOF mutations), affecting 266 individuals (Table 1) . Affected individuals were disproportionately likely to harbor a gene knockout (62% more likely; 0.05 events per affected individual versus 0.031 per unaffected individual, P = 0.0003 by random permutation testing), with the bulk of the excess arising from the rarest alleles (Table 1,  Supplementary Table 2 and Fig. 1a) . To control for possible differences in population and family structure (for example, founder effects and/or consanguinity in the Finnish and Middle Eastern cohorts), we also normalized to the background burdens of biallelic synonymous variants (see Methods and Supplementary  Tables 3-6 ). Individuals with autism spectrum disorder (ASD) continued to exhibit higher knockout rates after normalization (0.042 biallelic LOF events per affected individual versus 0.031 per unaffected individual, P = 0.008 by random permutation testing) ( Supplementary Fig. 2a ). Based on the observed ascertainment differentials between affected and unaffected individuals (0.050 versus 0.031, or 0.042 versus 0.031, after normalization), these burdens predict a contribution of biallelic LOF alleles to approximately 1-2% of ASD cases (see Methods).
We considered whether these findings might be extended to incorporate the impact of missense variation. Missense variation occurs much more frequently than truncating mutations, with a subset expected to be damaging. We evaluated potential missense contributions of two different types: all missense/non-synonymous variants (Nsyn), and damaging missense/non-synonymous variants (NsynD4, defined as missense changes classified as damaging by 4 or more predictive algorithms, representing 4% of all Nsyn events). Individuals with ASD exhibited an excess of biallelic events specifically involving a LOF allele in trans with an NsynD4 allele (Fig. 1b) , an effect that persisted after normalization to synonymous rates ( Supplementary Fig. 2b ). Similarly, considering biallelic events involving either rare LOF or NsynD4 alleles, we found that individuals with ASD demonstrated an excess of biallelic variation (P < 10 −4 ) with or without normalization ( Supplementary Fig. 2c and Fig. 1c ). Biallelic NsynD4 alleles were also found in excess in cases (Fig. 1c) , but this did not persist after normalization (P = 0.07, Supplementary Fig. 2c ). 
Letters

Nature GeNetics
Letters
Nature GeNetics
Alleles contributing to biallelic LOF knockout in cases were not in excess in the heterozygous state ( Supplementary Fig. 3) . Genes impacted by biallelic mutation also scored low with regard to haploinsufficiency 16 and gene constraint 17 ( Fig. 1d ,e and Supplementary Table 7 ), compared to known dominant and de novo ASD and ID genes 18 . These data support a recessive risk model, as opposed to the additive contributions of alleles acting codominantly.
ASD exhibits a striking male bias. Females with ASD exhibit a disproportionate burden of de novo and inherited single nucleotide variants (SNVs) and copy-number variants (CNVs), supporting a female protective/male susceptibility effect 19, 20 . We asked whether this also applies to rare recessive mutations. Unaffected males and females did not differ in the burdens of LOF knockout ( Fig. 2a and Supplementary Fig. 4a ). However, females with ASD exhibited a larger excess of biallelic LOF mutations ( Fig. 2a and Supplementary  Fig. 4a ). Similar patterns were observed when the analysis was extended to incorporate damaging missense variants, either alone (NsynD4; Fig. 2b and Supplementary Fig. 4b ) or grouped with LOF mutations (LOF or NsynD4; Fig. 2c and Supplementary Fig. 4c ). As observed before, LOF alleles were not in excess in the heterozygous state ( Supplementary Fig. 3 ). From these patterns, we conclude that the female protective/male susceptibility effect also extends to recessive mutations.
The ascertainment differentials observed led us to estimate the total contribution of biallelic mutation to ASD to be 3-5% (2% from LOF mutations, 1-3% from missense mutations). Furthermore, based on the ascertainment differentials, identifiable biallelic LOF or damaging missense alleles appeared to contribute to approximately 10% of female ASD cases in the ASC (Supplementary Fig. 4b ), suggesting that the category of biallelic mutation could be one of the largest genetic contributors to ASD in females.
To address the potential biological implications of these results, we examined the genes where biallelic mutations were found. We first focused on the category of strict biallelic LOF mutations, estimating from the observed ascertainment differentials that approximately 25-40% of those found in ASD patients (0.019 out of 0.05, or 0.011 out of 0.042, after normalization to synonymous burdens) contribute to their condition. A total of 109 unique genes were knocked out (biallelic LOF) in affected individuals in our dataset. We reasoned that the most relevant of these genes would be those Letters Nature GeNetics that are selected against biallelic inactivation in the general population. Therefore, we developed a filter to remove any gene that was also knocked out in 1 or more of 60,706 individuals sequenced as a part of the Exome Aggregation Consortium (ExAC: see Methods) 17 .
To test its effectiveness, we examined its impact on observed patterns and burdens of gene knockouts in ASD. Overall, 131 of the 227 (58%) gene knockouts observed in the ASC were also observed in the ExAC. Application of this filter reduced the overall burdens of observed biallelic knockout by half but left the ascertainment differentials intact ( Fig. 3a and Supplementary Fig. 5 ). This substantially increased the observed proportional excess of biallelic LOF mutation: after filtering, on average, individuals with ASD were approximately 2.6 times as likely to have biallelic LOF mutations as individuals without ASD (P = 0.002) (3.9× in females, P = 0.001, and 2.6× in males, P = 0.01) (Fig. 3a) .
We applied a similar logic to biallelic missense mutations. We reasoned that missense alleles encountered in the homozygous state in the general population are not likely to contribute to a recessive condition. Approximately 50% of rare, biallelic damaging missense events in the ASC involved an allele encountered in the homozygous state in the ExAC (Supplementary Fig. 6a and Supplementary Table 8 ). Filtering these events allowed us to discern for the first time a significant excess of rare biallelic damaging missense variation (that is, NsynD4) in cases compared to controls ( Supplementary Fig. 6a ), with an ascertainment differential of approximately 4%. Biallelic Nsyn variants were also in slight excess (P = 0.0037), which arose almost entirely from affected females ( Supplementary Fig. 6b ).
These results indicate that the observed excess in ASD is driven by genes and alleles that are biallelically constrained in the control population, strongly supporting the biological relevance of these findings.
De novo gene-disrupting mutations contribute strongly to ASD 6 . To examine possible interactions between de novo and biallelic genedisrupting events, we compared the burden of biallelic LOF events in cases with and without LOF de novo mutations ( Supplementary  Fig. 10 ) (ref. 6 ). An excess of rare biallelic LOF events is strongly evident in ASD cases lacking de novo LOF variants (Supplementary Fig. 10 , P = 0.0006). Their contribution in ASD cases with de novo LOF variants is harder to distinguish, since the observed difference in burdens of biallelic LOF events did not achieve statistical significance ( Supplementary Fig. 7 ). These may represent orthogonal risk categories, although larger sample sizes will be required to clarify this in the future.
After ExAC filtering, a total of 57 biallelically constrained genes harbored biallelic LOF mutations in at least one ASD case. Of these, we can estimate that approximately 60% of these (based on the observed burdens, see Methods), and 80% of the knockouts observed in females, probably confer an ASD risk. To further enrich for relevant genes, we also set aside 13 genes knocked out in one or more unaffected individuals in our ASC dataset ( Fig. 3b and Supplementary Table 7 ) and three that failed Sanger confirmation, leaving a final set of 41 genes that were specifically knocked out in individuals diagnosed with ASD, but never in the 66,558 controls (60,706 from the ExAC and 5,852 unaffected individuals from the ASC) (Supplementary Tables 9 and 10 ).
Several of these represent genes already implicated in disease. Eight (CA2, DDHD1, NSUN2, PAH, RARB, ROGDI, SLC1A1, USH2A) were associated with recessive genetic conditions involving neurodevelopmental delay (see Table 2 and Supplementary Information for clinical details). In at least six of these cases (CA2, NSUN2, PAH, RARB, ROGDI, USH2A), available medical and phenotypic records were concordant with the clinical features predicted from the genetic finding (Supplementary Information). Phenotypic data were either unavailable or incomplete, but not discordant, for other cases. In two cases, knockouts were encountered in genes that cause well-characterized autosomal recessive conditions without clear connection to autism (RFX5 and DNAI2, associated with autosomal recessive immunodeficiency and primary ciliary dyskinesia, respectively). In two other cases, knockouts were observed in genes associated with autosomal dominant disorders via recurrent gain-of-function mutations (IFITM5 and KIF22, causing osteogenesis imperfecta type V and spondyloepimetaphyseal dysplasia with joint laxity type 2, respectively). The phenotypic consequence of recessive LOF mutations for these two genes is unknown. Interestingly, KIF22 is one of 25 genes in the 593 kb core interval affected by 16p11.2 deletions 21 . KIF22 was proposed as one of two genes in the interval that demonstrates dosage sensitivity, with knockdown causing axon tract damage and behavioral defects in zebrafish 22 ; disruption of a KIF22 ortholog in Drosophila causes defects in synapse development 23 . Several of the remaining 33 genes are of strong neurobiological interest. One affected individual bore a homozygous LOF mutation (p.E48X) in SLC1A1, where mutations have been linked to , an extremely rare disorder with prior associations with intellectual disability 25, 26 and obsessive compulsive disorder 24 . SLC1A1 encodes a brain-expressed, activity-regulated glutamate transporter 27, 28 that modulates glutamatergic neurotransmission via a variety of mechanisms [29] [30] [31] [32] [33] [34] SLC1A1 knockout in mice results in altered locomotor behavior 35 and learning and memory defects 36 . Two brothers with ASD bore homozygous stop-gain mutations in FEV (FEV transcription factor, ETS family member), which encodes a transcription factor that is required for both the development and function of serotonergic neurons (Supplementary Fig. 8a ). These neurons send projections that ramify broadly throughout the central nervous system (Supplementary Fig. 8b) , and have wideranging neuromodulatory effects on many physiological states and behaviors, including mood, aggression, anxiety, sleep and movement 37 . Serotonergic dysfunction has been strongly implicated in neuropsychiatric conditions including ASD 38 , schizophrenia and mood disorders 37 . In mice, Fev/Pet-1 has been shown to be highly expressed in the serotonergic raphe nuclei 39 , and inactivation of Fev during development 40 or adulthood 41 results in the depletion of serotonergic neurons and neurobehavioral changes including anxiety and aggression 40, 41 . Human FEV is also expressed in the serotonergic raphe neurons in the adult brain 42, 43 ; we found similar results via in situ hybridization analysis of human fetal brain ( Supplementary Fig. 8c-f) . The older affected brother was diagnosed with autism and had a measured IQ of 69. He exhibited severe, stereotyped aggressive and self-injurious behaviors. He had a body mass index of 25.6 (99%) and mildly dysmorphic facial features. The electroencephalogram showed bilateral Rolandic focus with generalization. The younger affected brother was diagnosed with pervasive developmental disorder-not otherwise specified and intellectual disability (IQ not measured), had a body mass index of 17.7 (91%) and no facial dysmorphism (further details can be found in the Supplementary Information). We are not aware of any previous report of a human LOF phenotype for FEV.
Gene knockouts were also identified in FCHSD2, encoding a cytoskeletal adapter protein that is highly expressed in human fetal brain and is the human homolog of Drosophila Nervous Wreck 44 , NCOA7, a brain-specific transcriptional coactivator for steroid and nuclear hormone receptors 45 and MOB1B, a downstream effector in the Hippo signaling pathway, a pathway recently implicated in the regulation of brain size 46 . Many additional genes in the candidate set have abundant brain expression (BRMS1L, ELOF1, GCN1L1, NUPR1, SLC22A6) but less clear neurobiological activity.
We also expanded our scope to incorporate biallelic missense mutations. There were 409 distinct genes that harbored biallelic, damaging missense mutations in cases but not in controls ( Supplementary Fig. 9 and Supplementary Table 11 ). Only one gene was independently hit in multiple families: aminomethyltransferase (AMT), an established cause of non-ketotic hyperglycinemia. Hypomorphic mutations in AMT have previously been reported to cause ASD without the non-ketotic hyperglycinemia's characteristic metabolic abnormalities. No other gene was hit more than once, so larger sample sizes are necessary to establish any of these genes as ASD genes on this basis alone (Supplementary Table 11 and Supplementary Figs. 10 and 11) . However, there were 13 cases where the affected individuals carried biallelic mutations in alleles of established medical importance (in ClinVar as pathogenic or likely pathogenic; Table 3, Supplementary Table 12 and Supplementary Information). All were diagnostic of genetic disorders with known neurodevelopmental consequences, including classic metabolic diseases, mitochondrial depletion syndrome and other syndromic conditions. When combined with the previously described 8 LOF cases, biallelic mutations in known genes constituted approximately 1% of our cohort (21 out of 2,343 affected individuals), underscoring the importance of clinical screening for monogenic recessive conditions in this patient population.
Our study extends prior estimates of the contribution of recessive mutations to ASD 13, 14 and proves that the female protective/ male susceptibility effect in ASD also applies to biallelic mutations. Expanding these efforts to larger ASD cohorts should offer a path forward to delineate previously unknown neurobiological mechanisms in autism.
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Methods Whole-exome data analyses. Whole-exome sequencing data were gathered as part of the ASC 47 . We focused our analysis on nine datasets generated using the Illumina sequencing platform (Supplementary Table 1 ). Alignment and variant calling were performed as described previously 6 . Low-quality variants were filtered with the following criteria: (1) SNPs with genotyping quality < 20; (2) SNPs not passing the standard PASS filter; and (3) all indels (due to excessive false positives leading to spurious frameshift calls). Variant annotation was performed using ANNOVAR 48 v.2017June01 to add allele frequencies, functional predictions, conservation and gene annotations including Online Mendelian Inheritance in Man and Human Gene Mutation Database (HGMD) 49 disease associations. Allele frequencies were also calculated for each contributing cohort and across the entire collection of ASC samples analyzed. Variants were categorized by their predicted impact into synonymous, non-synonymous (missense) or LOF (altering a canonical splice site or resulting in a stop-gain). Additional classification of damaging missense variants (NsynD4) was performed for variants predicted to be deleterious by at least 4 out of 6 algorithms (SIFT 50 ). Phasing was performed using Beagle v.4 (ref. 55 ) on the ASC dataset. Variant call formats were subdivided by chromosome and cohort before processing with Beagle using default parameters.
Biallelic burden calculations. Allele frequency filtration was performed as described in the text using available public databases (1000 Genomes, Exome Variant Server, ExAC). For rare variant calculations at the maximum allele frequencies of 0.1, 0.5, 1, 5 and 10%, additional cohort-specific filters (cohortspecific allele frequencies of 5 or 10%) were applied to account for allelic variants that may be prevalent in a population but are not well represented in existing control databases. The burdens of homozygous and compound heterozygous variants were then counted for each cohort and for the entire ASC, stratifying by affected/unaffected status, sex and mutational category (LOF, Nsyn, NsynD4, Syn).
To control for potential differences in underlying family and population structure of some of the constituent cohorts, we also measured rates of synonymous biallelic variation. In two cohorts (from the Middle East and Finland, respectively), rates of biallelic synonymous variation in affected individuals were higher than rates of biallelic synonymous variation in unaffected individuals (Supplementary Table 3 ). Therefore, for these cohorts, we normalized the LOF, NsynD4 and Nsyn burden calculations to the background rate of biallelic synonymous variation, to isolate the impact of biallelic LOF variation independent of background homozygosity in these cohorts.
The contribution of mutations to ASD risk was estimated using the following approach. First, the ascertainment differential is calculated as the difference between the burden of biallelic mutations in cases and in controls and represents the estimated fraction of mutations that contribute to ASD. For example, an ascertainment differential of 0.01 suggests that 1% of cases have a biallelic mutation contributing to ASD risk. The fraction of observed biallelic mutations contributing to disease is then calculated as the ascertainment differential divided by the total mutation burden in cases. For example, given a burden of 0.025 biallelic LOF events in cases and 0.01 biallelic LOF events in controls, the ascertainment differential is 0.015 and the percentage of mutations identified that contribute to disease risk is 0.015 divided by 0.025, or 60%.
For burden comparisons, significance was assessed by permutation testing using 10,000 random assignments of diagnostic categorization to individuals in the study. A significance threshold of P < 0.05 (that is, without correction for multiple testing) was used since the allele frequency cutoffs and variant annotation classes (LOF, LOF + NsynD4, LOF or NsynD4, NsynD4, Nsyn) analyzed are not discrete. We note that all ExAC-filtered biallelic burden results (that is, excess biallelic LOF, NsynD4 and Nsyn mutations, summarized in Fig. 3 and Supplementary Figs. 5 and 6 ) were significant even with the application of maximally conservative Bonferroni correction (for example, P < 0.01, assuming five fully independent hypotheses).
ExAC filtration. To generate a list of genes commonly inactivated by biallelic LOF mutation, we analyzed whole-exome data from 60,706 individuals compiled by ExAC 17 . We applied ANNOVAR to systematically re-annotate all variants from ExAC against RefSeq complete protein-coding genes (v.2017June01). Since phasing was unavailable, we focused on genes bearing putative homozygous LOF variants (any variant in stop-gain, frameshift or canonical splicing change). Homopolymer expansions/contractions in canonical splice regions were ignored, since expansions and contractions in these regions are common and have little impact on splicing. With these parameters, a total of 2,986 genes were found to be inactivated by homozygous stop-gain, frameshift or canonical splice site mutation in ExAC. We also used this re-annotated dataset to generate a list of ExAC alleles encountered in the homozygous state, to identify missense and other mutations that are more likely to be clinically benign. For the final LOF candidate genes presented in Supplementary Tables 9 and 10 , contributory alleles were also confirmed to be absent in the homozygous state in the Genome Aggregation Database dataset 17 .
Variant confirmation. Sanger sequencing was used to confirm the accuracy of exome variant calls for a subset of LOF and NsynD4 variants with an empirical validation rate of 96% (107 of 114 alleles tested). These included all LOF alleles reported in this study for which DNA samples were available. If DNA samples were not available, we noted the presence of allelic variants in known databases and/or whether predicted genotypes followed Mendelian segregation patterns in parental exome data (where available) as additional support.
Human tissue collection and in situ hybridization for FEV. Human embryonic and fetal tissues were obtained from the MRC/Wellcome Trust Human Developmental Biology Resource (www.hdbr.org) 56 following appropriate consent from the women involved and adhering to the relevant Human Tissue Authority guidelines with approval from Research Ethics Committee, NRES Committee North East, Newcastle & North Tyneside 1.
RNA probes were produced by amplifying human embryonic complementary DNA using a forward primer to FEV (NM_017521, nucleotides 1286-1305) tagged with a T7 RNA promoter sequence and a reverse primer (NM_017521, nucleotides 1862-1843) tagged with an SP6 RNA promoter sequence (Supplementary Table 13 ). The resulting fragment was transcribed in vitro using the DIG RNA Labeling Kit (Roche).
The in situ hybridizations were performed as described previously 47 , except that a 60 ng RNA probe in 100 μl ULTRAhyb (Ambion) per slide was used for the hybridization. The post-hybridization washes were modified as follows: slides were washed for 10 min in 5× SSC buffer, twice in 2× SSC, 50% formamide/1× SSC, 1× SSC and finally in 0.1× SSC. The hybridization incubation and all posthybridization steps were performed at 63. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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